Re Application of: Yechiel HAI et al

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit: 1653

Examiner: D. Lukton Washington, D.C.

Atty.'s Docket: SHAI=2

Date: March 19, 2002

OR

OR

RECEIVED

MAR 2 2 2002

TECH CENTER 1600/2900

Application No.: 09/367,714 7RADEWAY Conf. No. 4669

Filed: January 14, 2000

For: ANTIPATHOGENIC SYNTHETIC PEPTIDES AND COMPOSITIONS COMPRISING THEM

or Antipathogenic stathetic peptibes and compositions compassing their

THE COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

Sir:

[] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

[XX] No additional fee is required.

[] The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	* 27	MINUS	** 30	0
INDEP.	* 1	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

SWALL LIVITI				
	RATE	ADDITIONAL FEE		
×	9	\$		
_x	42	\$		
+	140	\$		
NAL F	\$			
	X X +	x 9 x 42		

SMALL ENTITY

OTHER THAN SMALL ENTITY				
	RATE	ADDITIONAL FEE		
х	18	\$		
х	84	\$		
+	280	\$		
	TOTAL	\$		

- If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below

1	it is necessy pennioned for an extension of time in accordance with 37 C	FR 1.130(a). The appropriate fee required by 37 Cr	-K 1.17 is calculated as shown below.
	Small Entity	Other Than Small Entity	,
	Response Filed Within	Response Filed Within	t.
	[] First - \$ 55.00	[] First - \$ 110.00	
	[] Second - \$ 200.00	[] Second - \$ 400.00	
	[] Third - \$ 460.00	[] Third - \$ 920.00	RECEIVED
	[] Fourth - \$ 720.00	[] Fourth - \$ 1440.00	OLIVED
	Month After Time Period Set	Month After Time Period Set	MAR 2 1 2002
	[] Less fees (\$) already paid for month(s) extension of	of time on	
l	Please charge my Deposit Account No. 02-4035 in the amount of \$	TC 1700	
	Credit Card Payment Form, PTO-2038, is attached, authorizing payme	ent in the amount of \$	
1	A check in the amount of \$ is attached (check no.).		

The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does <u>not</u> include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

Roger L. Browdy Registration No. 25,618

Facsimile: Telephone:

(202) 737-3528 (202) 628-5197 MAR 1 9 2002 BY

TECH CENTER IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: SHAI=2

In re Application of:

Conf. No.: 4669

Yechiel SHAI et al

Art Unit: 1653

Appln. No.: 09/367,714

Examiner: D. Lukton

Filed: January 14, 2000

Washington, D.C.

For: ANTIPATHOGENIC SYNTHETIC

March 19, 2002

PEPTIDES AND COMPOSITIONS)
COMPRISING THEM)

AMENDMENT

RECEIVED

MAR 2 1 2002

Honorable Commissioner for Patents Washington, D.C. 20231

TC 1700

Sir:

In response to the Office Action of February 15, 2002, please amend as follows:

IN THE CLAIMS

Delete claims 15-17 and 36 without prejudice towards the continuation of prosecution thereof in divisional applications.

Please amend claims 1, 2, 6, 7, 9, 11-14, 20, 21, 34 and 35 as follows:

1 (Thrice-Amended). A non-hemolytic cytolytic peptide having a selective cytolytic activity manifested in that it has a cytolytic activity on pathogenic cells, said

FI

F